drugset / Trial / NCT01588353
Collagenase Option for Reduction of Dupuytren's Contracture in Japan
NaSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture. To determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture.
Timeline
- Start
- 2012-05
- Primary completion
- 2014-01
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.58 mg | — |